Comparison of effects of short-term intensive insulin therapy with Insulin degludec and Insulin aspart and basal-prandial insulin in patients with type 2 diabetes mellitus
Objective:To compare effects of short-term intensive treatment of type 2 diabetes mellitus with Insulin degludec and Insulin aspart and basal-prandial insulin. Methods:The clinical data of 80 patients with type 2 diabetes mellitus admitted to this hospital from January 2021 to October 2023 were retrospectively analyzed. According to different treatment methods,they were divided into observation group and control group,40 cases in each group. The control group was treated with short-term intensive insulin therapy with basal-prandial insulin,while the observation group was treated with Insulin degludec and Insulin aspart. The levels of blood glucose indexes[fasting blood glucose (FPG),2 h postprandial blood glucose (2hPG),glycosylated hemoglobin (HbA1c)],islet β cell function[islet β cell function index (HOMA-β),homeostasis model assessment of insulin resistance (HOMA-IR)],serum fibroblast growth factor-23 (FGF-23) and progranulin (PGRN),and the incidence of adverse reactions were compared between the two groups. Results:After the treatment,the levels of FPG,HbA1c and 2hPG in the two groups were lower than those before the treatment,those in the observation group were lower than the control group,and the differences were statistically significant (P<0.05). After the treatment,the levels of HOMA-β in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the HOMA-IR levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant (P<0.05). After the treatment,the levels of FGF-23 and PGRN in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). Further,the incidence of adverse reactions in the observation group was 5.00％ (2/40),which was lower than 22.50％ (9/40) in the control group,and the difference was statistically significant (P<0.05). Conclusions:Insulin degludec and Insulin aspart can improve the islet β cell function,reduce the blood glucose levels and the incidence of adverse reactions,and reduce the insulin resistance in the patients with type 2 diabetes mellitus. Moreover,it is superior to simple the short-term intensive treatment with basal-prandial insulin.
Type 2 diabetes mellitusInsulin degludec and Insulin aspartBasal-prandial insulinIslet β-cell function
万方数据
维普
